Compared to Estimates, Privia Health (PRVA) Q2 Earnings: A Look at Key Metrics

For the quarter ended June 2026, Privia Health (PRVA) reported revenue of $632.63 million, up 21.4% over the same period last year. EPS came in at $0.07, compared to $0.02 in the year-ago quarter.

The reported revenue represents a surprise of +8.76% over the Zacks Consensus Estimate of $581.67 million. With the consensus EPS estimate being $0.08, the EPS surprise was -12.5%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Privia Health performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Practice Collections: $970 million compared to the $909.89 million average estimate based on three analysts.
• Care Margin: $132.15 million compared to the $130.16 million average estimate based on three analysts.
• Value-Based Care Attributed Lives (as of end of period): 1.65 million compared to the 1.58 million average estimate based on three analysts.
• Implemented Providers (as of end of period): 5,644 compared to the 5,682 average estimate based on three analysts.
• Platform Contribution: $68.99 million versus $66.4 million estimated by three analysts on average.

View all Key Company Metrics for Privia Health here>>>

Shares of Privia Health have returned -11.9% over the past month versus the Zacks S&P 500 composite's +3.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

7 Best Stocks for the Next 30 Days

Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."

Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.

See them now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Privia Health Group, Inc. (PRVA): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research